Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px

Deals > All

Total search results: 9868 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 97 98 99  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
AgomAb Therapeutics–Instinctif Partners: public relations, 201901 service existent by Instinctif für UK + RoW 2019-04-03
AgomAb Therapeutics–Omnes Capital: investment, 201904 financing round Series A totalling €21m incl co-investor Omnes 2019-04-03
AgomAb Therapeutics–Pontifax: investment, 201904 financing round Series A totalling €21m incl co-investor Pontifax 2019-04-03
AgomAb Therapeutics–SEVERAL: investment, 201904 financing round Series A €21m co-led by V-Bio Ventures + Advent France Biotechnology 2019-04-03
AgomAb Therapeutics–V-Bio Ventures: investment, 201904 financing round Series A totalling €21m incl co-lead investor V-Bio Ventures 2019-04-03
Bayer–Editas Medicine: genome editing + cell therapy, 201904– strategic research collab + cross-license CRISPR + iPSC technologies BlueRock Tx 2019-04-03
Dyne Therapeutics–Atlas Venture: investment, 201904 financing round Series A totalling $50m incl founding investor Atlas Venture 2019-04-03
Dyne Therapeutics–Forbion: investment, 201904 financing round Series A totalling $50m incl co-investor Forbion 2019-04-03
Dyne Therapeutics–MPM Capital: investment, 201904 financing round Series A totalling $50m incl co-investor MPM Capital 2019-04-03
Dyne Therapeutics–SEVERAL: investment, 201904 financing round Series A $50m from founding investor Atlas Venture plus Forbion + MPM Capital 2019-04-03
LabCorp–Qiagen: molecular companion diagnostics, 201904– collab LabCorp joins Qiagen’s Day-One Lab Readiness program 2019-04-03
Rave LLC–Bruker Corp: investment, 201904 acquisition €na by Bruker 2019-04-03
Chr Hansen–Lonza: live biotherapeutics, 201904– collab establishment 50/50 joint venture for developing + manufacturing microbiome treatments 2019-04-02
Immunic–Rx Communications: public relations, 201904 service existent by Rx Communications Group 2019-04-02
Khloris Biosciences–Bayer: investment, 201904 seed financing €na from Leaps by Bayer 2019-04-02
Cambridge Innovation Capital–SEVERAL: investment, 201904 financing round £150m with Univ Cambridge as cornerstone investor 2019-04-01
Cambridge Innovation Capital–Univ Cambridge: investment, 201904 financing round totalling £150m incl cornerstone investor Univ Cambridge 2019-04-01
Digital China Health–Congenica: bioinformatics, 201904 collab existent DCH is commercial partner for Sapientia s/w in China 2019-04-01
IFM Therapeutics–Novartis: investment, 201904– acquisition 100% of IMF Tre for upfront payment + milestones ANNOUNCED 2019-04-01
Karuna–Alexandria Real Estate: investment, 201903–201904 financing round Series B totalling $80m incl co-investor Alexandria Venture Investments 2019-04-01
Karuna–ARCH Venture: investment, 201903–201904 financing round Series B totalling $80m incl exisiting + lead investor ARCH Venture Partners 2019-04-01
Karuna–Eventide Asset Management: investment, 201903–201904 financing round Series B totalling $80m incl co-investor Eventide 2019-04-01
Karuna–Fidelity: investment, 201903–201904 financing round Series B totalling $80m incl co-investor Fidelity Management & Research 2019-04-01
Karuna–Nan Fung: investment, 201903–201904 financing round Series B totalling $80m incl co-investor Pivotal BioVenture Partners 2019-04-01
Karuna–Partner Fund Management: investment, 201903–201904 financing round Series B totalling $80m incl co-investor Partner Fund Management 2019-04-01
Karuna–PureTech Health: investment, 201903–201904 financing round Series B totalling $80m incl exisiting investor PureTech Health 2019-04-01
Karuna–Sands Capital: investment, 201903–201904 financing round Series B totalling $80m incl co-investor Sands Capital 2019-04-01
Karuna–SEVERAL: investment, 201903–201904 financing round Series B $80m led by ARCH Venture Partners incl $5m debt conversion 2019-04-01
Karuna–Sofinnova: investment, 201903–201904 financing round Series B totalling $80m incl $12m from new investor Sofinnova Investments 2019-04-01
Karuna–Wellcome Trust: investment, 201903–201904 financing round Series B totalling $80m incl exisiting investor Wellcome Trust 2019-04-01
Mogrify–United Kingdom (govt): grant, 201904 SBRI Healthcare funding for developm of cell therapy for osteoarthritis 2019-04-01
Bayer–ProteoNic: rec protein production technology, 201903– license non-excl €na to use 2G UNic technology to boost rec protein production 2019-03-28
Cellnovo–NONE: investment, 201903 in administration 2019-03-28
Inivata–Consilium: public relations, 201903 service existent by CSC 2019-03-28
Inivata–LifeSci: public relations, 201903 service existent IR by LifeSci Advisors 2019-03-28
Polyneuron–New Enterprise Associates: investment, 201903 financing round Series A totalling CHF22.5m incl new + co-lead investor NEA 2019-03-28
Polyneuron–SEVERAL: investment, 201903 financing round Series A CHF22.5m led by Sofinnova Partners + incl NEA 2019-03-28
Polyneuron–Sofinnova: investment, 201903 financing round Series A totalling CHF22.5m incl new + lead investor Sofinnova Partners 2019-03-28
Selvita–Trout Group: public relations, 201903 service existent media relations + IR by The Trout Group 2019-03-28
Univ College London–ArcherDx: PCR technology, 201903– collab €na use of AMP technology in UCL-sponsored UK lung cancer diagnostics TRACERx study 2019-03-28
H4Orphan Pharma–Cerenis: investment, 201903–201904 excl merger negotations w Cerenis owning 59% of combined company TERMINATED 4/19 2019-03-27
Cytena–High-Tech Gründerfonds: investment, 201903 financing round Series A totalling €3.m incl HTGF + two private investors 2019-03-26
Cytena–SEVERAL: investment, 201903 financing round Series A €3.m from HTGF + two private investors 2019-03-26
Evotec–Mark Foundation: investment, 201903–202102 research funding for two years €na by Mark Foundation with potential financial returns 2019-03-26
Lundbeck–Enamine: chemical compound libraries, 201903– supply expansion discovery chemistry services by Enamine 2019-03-26
Menarini–Curetis: molecular diagnostics, 201903– distribution excl long-term of Unyvero platform + cartridges in Europe by Menarini Diagnostics 2019-03-26
Synerkine Pharma–SEVERAL: investment, 201903 financing round Series A €3.3m from Thuja Capital + private investor + company founders 2019-03-25
Synerkine Pharma–Thuja Capital: investment, 201903 financing round Series A totalling €3.3m incl Thuja Capital + private investor + company founders 2019-03-25
Brammer Bio–Thermo Fisher: investment, 201903– acquisition $1.7b in cash from Ampersand Capital Partners + Founders ANNOUNCED 2019-03-24
Exscientia–Edelman: public relations, 201803 service existent by Edelman PR 2019-03-22
Hookipa–SEVERAL: investment, 201903– IPO $84m+$12.6m with 6m+900k shares common stock at Nasdaq Global Select Market 2019-03-22
Celgene–Exscientia: drug discovery software, 201903–202203 collab $25m upfront + milestones + royalties 3y AI drug discovery partnership 2019-03-21
Pierre Fabre–Institut Curie: cancer immunotherapy, 201903– collab extension I-O drug target discovery with IRPF 2019-03-21
United Kingdom (govt)–Cambridge Cancer Genomics: personalised immuno-oncology, 201903– collab long-term of Genomics England + CCG.ai 2019-03-21
Verona Pharma–ICR: public relations, 201903 service existent by ICR in US 2019-03-21
Verona Pharma–Novo Group: investment, 201903 existent investment Novo Holdings owns 11.76% shareholding in Verona Pharma plc 2019-03-21
Atlatl–Miltenyi Biotec: CliniMACSProdigy platform, 201903– collab co-founding of Atlatl-Macs Center for Gene + Cell Therapy in Shanghai 2019-03-20
NeoPhore–Optimum Strategic Communications: public relations, 201903 service existent by Optimum 2019-03-20
Pfizer–Vivet Therapeutics: VTX-801, collab developm €45m (incl acqu 15% share) + €560m milestones (incl acquisition of Vivet) 2019-03-20
Vivet Therapeutics–Pfizer: investment, 201903 acquisition 15% equity interest plus excl option to acquire all outstanding shares 2019-03-20
Oncimmune–Consilium: public relations, 201903 service existent by CSC 2019-03-19
Oncimmune–Qiagen: investment, 201903 up to 1.34% shareholding for Qiagen after Oncimmune’s acquisition of Protagen 2019-03-19
Protagen–Oncimmune: investment, 201903 acquisition of Portagen for up to £4.11m in up to 2.636m ordinary shares 2019-03-19
Mogrify–United Kingdom (govt): grant, 201903 Innovate UK funding £420k to use big data analysis to advance cell therapies 2019-03-18
Arxspan–Bruker Corp: investment, 201903 acquisition €na of Arxspan LLC by Bruker Corp 2019-03-14
Merck (DE)–Iktos: drug discovery services, 201903– collab using AI technology for small molecule drug discovery projects 2019-03-14
Metrion Biosciences–o2h: investment, 201903 financing round incl o2h Ventures Therapeutics Fund 2019-03-14
Metrion Biosciences–SEVERAL: investment, 201903 financing round incl o2h Ventures Therapeutics Fund 2019-03-14
Rocket Pharmaceuticals–MolMed: gene therapy, 201903– collab expansion developm + manufacture of lentiviral vectos by MolMed for three new indications 2019-03-13
Biogen–Fujifilm: biologics contract manfuacturing, 201903– supply manufacturing of biologicals for Biogen incl Tysabri 2019-03-12
Biogen–Fujifilm: investment, 201903– acquisition up to $890m in cash of Biogen’s Biologics Manufacturing Site in Hillerød Denmark 2019-03-12
BMS–Biocartis: molecular companion diagnostics, 201903– collab Idylla MSI testing with cancer immunotherapies 2019-03-12
Oxford BioMedica–Microsoft: bioinformatics, 201903–202102 collab r+d using MS Azure cloud + machine learing to optimise gene therapy vectors 2019-03-12
AstraZeneca–Seres Therapeutics: microbiomics, 201903–202202 collab research 3y $20m + research funding for microbiomics to support I-O therapies 2019-03-11
Snipr Biome–Life Sciences Partners: investment, 201903 financing round Series A totalling $50m incl co-lead investor LSP 2019-03-11
Snipr Biome–Lundbeck: investment, 201903 financing round Series A totalling $50m incl existing + co-lead investor Lundbeckfonden Emerge 2019-03-11
Snipr Biome–North-East Family Office: investment, 201903 financing round Series A totalling $50m incl co-investor North-East Family Office 2019-03-11
Snipr Biome–SEVERAL: investment, 201903 financing round Series A $50m co-led by Lundbeckfonden Emerge + Life Sciences Partners 2019-03-11
Snipr Biome–Wellington Partners: investment, 201903 financing round Series A totalling $50m incl co-investor Wellington Partners 2019-03-11
Qiagen–Tecan: lab automation, 201903– collab direct supply of Tecan Fluent workstation for sample to labs using QuantiFeron-TB Gold Plus test 2019-03-08
Gilde Investment–SEVERAL: investment, 201903 final close €200m Gilde Healthcare Service III fund incl PGGM/PF Zorg en Welzijn + Rabo Corp Investments 2019-03-07
SOM Biotech–SEVERAL: investment, 201903 financing round €7m led by European family holding 2019-03-07
BPCE–SEVERAL: investment, 201903 first closing €na of Seventure Health for Life Capital II Fund with final target size of over €200m 2019-03-05
Novasep–Sartorius: chromatography, 201903– collab developm of systems for membrane chromatography SSB 2019-03-05
abcr GmbH–Enzymicals: enzymes, 201903– collab distribution expansion ww sale of all catalogue products of Enzymcials by acbr 2019-03-04
Ascendis Pharma–SEVERAL: investment, 201903– public offering $400m+$60m ADSs 2019-03-04
Nightstar Therapeutics–Biogen: investment, 201903– acquisition $877m in cash at $25.5/share ANNOUNCED 2019-03-04
NovaGo Therapeutics–Neurimmune: investment, 201903 financing round Series A totalling CHF10m incl co-lead investor + strategic partner Neurimmune 2019-03-04
NovaGo Therapeutics–Pureos Bioventures: investment, 201903 financing round Series A totalling CHF10m incl co-lead investor Pureos Bioventures 2019-03-04
NovaGo Therapeutics–SEVERAL: investment, 201903 financing round Series A CHF10m co-led by Pureos Bioventures + Neurimmune 2019-03-04
Anaeropharma Science–BPCE: investment, 201903 existent portfolio company of Seventure Partners 2019-03-01
CEPI–CureVac: mRNA vaccine production technology, 201903–202202 collab up to $34m developm of mobile mRNA printing facility 2019-03-01
Humedics–BPCE: investment, 201903 existent portfolio company of Seventure Partners 2019-03-01
MycoTechnology–BPCE: investment, 201903 existent portfolio company of Seventure Partners 2019-03-01
TargEDys–BPCE: investment, 201903 existent portfolio company of Seventure Partners 2019-03-01
TreeFrog Therapeutics–SEVERAL: grant, 201903 non-dilutive funding €600k from Nouvelle-Aquitaine Region + Bpifrance + French Ministry of Research 2019-03-01
iOnctura–Optimum Strategic Communications: public relations, 201902 service existent by Optimum 2019-02-28
JnJ–AdoRx: adenosine receptor antagonists, 201902– collab developm + excl option €na lung cancer drugs with JnJ Innovation 2019-02-28
Sarepta–Centogene: molecular diagnostics, 201902–202002 collab service identifying DMD patients in MENA region by Centogene 2019-02-28
CN Innovations–MIT: organ-on-a-chip technology, 201902– license excl for organ-on-a-chip with human tissues fomr up to 10 organs for CN Bio 2019-02-27
next pagenext page 1 2 3 ... 97 98 99  next pagenext page



Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px

» top